Compare Albemarle Corp. (ALB) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Ginkgo Bioworks Holdings Inc — how do they compare? Albemarle Corp. trades at $128.3 (market cap $15.27B), while Ginkgo Bioworks Holdings Inc trades at $7.42 (market cap $505.73M). The key difference: Albemarle Corp. is far larger — about 30.2× Ginkgo Bioworks Holdings Inc's market cap, and Albemarle Corp. pays a 1.27% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| ALB | DNA | |
|---|---|---|
Market Cap | $15.27B | $505.73M |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $16.14 |
52-Week Low | $72.58 | $5.48 |
Enterprise Value | $17.75B | $607.68M |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALB trades at $128.21, down 2.29% today, amid a mixed technical picture with bullish moving averages but overbought RSI signals. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.75, driven by improved lithium pricing and cost savings. Revenue for 2025 was $5.14B, though net income remained negative at -$510.63M. Analyst consensus is a Buy with a $184.50 price target, reflecting optimism for recovery.
Outlook is cautiously optimistic as lithium demand supports earnings growth, but Q3 guidance warns of sequential declines. Key risks include volatile lithium prices and execution challenges. The stock offers potential upside to analyst targets if operational improvements continue, but investors face margin pressure and macroeconomic headwinds.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
